Cargando…

Dose, duration and strain of bacillus Calmette–Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials

BACKGROUND: Intravesical bacillus Calmette–Guerin (BCG) instillation is widely used as an adjuvant therapy after transurethral resection of bladder tumor (TURBT) in patients with intermediate- and high-risk nonmuscle invasive bladder cancer (NMIBC). However, the effective dose, duration, and strain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quan, Yongjun, Jeong, Chang Wook, Kwak, Cheol, Kim, Hyeon Hoe, Kim, Hyung Suk, Ku, Ja Hyeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	7300
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662397/ https://www.ncbi.nlm.nih.gov/pubmed/29049231 http://dx.doi.org/10.1097/MD.0000000000008300

Ejemplares similares

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
por: Zeng, Shuxiong, et al.
Publicado: (2015)

Pyuria as a Predictive Marker of Bacillus Calmette–Guérin Unresponsiveness in Non-Muscle Invasive Bladder Cancer
por: Suh, Jungyo, et al.
Publicado: (2021)

Does reduced E-cadherin expression correlate with poor prognosis in patients with upper tract urothelial cell carcinoma?: A systematic review and meta-analysis
por: Tae, Bum Sik, et al.
Publicado: (2019)

Should intravesical Bacillus Calmette–Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
por: Yuk, Hyeong Dong, et al.
Publicado: (2018)

Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting
por: Yuk, Hyeong Dong, et al.
Publicado: (2019)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

Preoperative Plasma Fibrinogen Level as a Significant Prognostic Factor in Patients With Localized Renal Cell Carcinoma After Surgical Treatment
por: Lee, Hakmin, et al.
Publicado: (2016)

Pembrolizumab in bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057)
por: Kumar, Bhuwan
Publicado: (2021)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study
por: Jian, Xiaoming, et al.
Publicado: (2019)

Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations
por: Wroclawski, Marcelo Langer, et al.
Publicado: (2019)

Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008)

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
por: Ko, Dayoung, et al.
Publicado: (2022)

Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials
por: Kim, Hyung Suk, et al.
Publicado: (2017)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis
por: Ku, Ja Hyeon, et al.
Publicado: (2015)

Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients
por: Kim, Hyung Suk, et al.
Publicado: (2015)

Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021)

Histological variant as the significant predictor of survival in patients with lymph node positive urothelial carcinoma of the bladder
por: Kim, Hyung Suk, et al.
Publicado: (2015)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer
por: Rachakonda, Tara, et al.
Publicado: (2017)

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016)

Single course of intravesical Bacillus Calmette–Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study
por: Mohamed, Mohamed Bakr, et al.
Publicado: (2020)

The prognostic impact of perioperative blood transfusion on survival in patients with bladder urothelial carcinoma treated with radical cystectomy
por: Lee, Joong Sub, et al.
Publicado: (2015)

Is Bladder Tumor Location Associated with Prostate Cancer Detection after Intravesical Bacillus Calmette-Guérin Instillation?
por: Hong, Sungwoo, et al.
Publicado: (2014)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
por: Bazarbashi, Shouki N., et al.
Publicado: (2016)

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis
por: Broughton, Edward I., et al.
Publicado: (2022)

Systemic Granulomatous Reaction Secondary to Treatment of Bladder Cancer with Bacillus Calmette-Guerin
por: Valentini, Caterina Giovanna, et al.
Publicado: (2012)

VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951)

Disseminated Bacillus Calmette-Guérin Infection and Immunodeficiency
por: Bernatowska, Ewa Anna, et al.
Publicado: (2007)

Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018)

Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021)

Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity
por: Parmar, Kanak, et al.
Publicado: (2021)

100 years of the Bacillus Calmette-Guérin vaccine
por: Bettencourt, Paulo J.G., et al.
Publicado: (2021)

Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor
por: Kang, Minyong, et al.
Publicado: (2016)

Monthly maintenance protocol Bacillus Calmette–Guerin as a viable alternative to Southwest Oncology Group maintenance protocol in nonmuscle-invasive bladder cancer: A prospective randomized study
por: Gupta, Naveen Kumar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l36bs0kr3m9lscedceo5a7a097